Literature DB >> 16015088

Retroprosthetic membranes in AlphaCor patients: risk factors and prevention.

Celia R Hicks1, Stephen Hamilton.   

Abstract

PURPOSE: To report retroprosthetic membrane (RPM) formation in association with AlphaCor and identify risk factors for their formation and strategies for prevention and management.
METHODS: Review of AlphaCor data and case histories and literature review.
RESULTS: RPMs occurred with AlphaCor in 14 (9.3%) cases. We find significant associations with systemic risk factors (race, hypertension, diabetes mellitus) rather than ocular history, but perioperative management may also be related to risk of RPM development. Histology demonstrates a fibrovascular tissue resembling scarred corneal tissue. Similar histologic findings have been reported for other devices.
CONCLUSION: Retrocorneal membranes and RPMs with earlier keratoprostheses have frequently been reported without specific identifiable causes. Diabetes is known to be associated with intraocular membrane formation. This study demonstrates that systemic factors affect the risk of RPM formation with AlphaCor. In cases identified as at greater risk of membrane formation, peri- and postoperative therapies such as steroids, non-steroidals, heparin or rTPA should be considered. In our series, several therapeutic and surgical strategies appear effective but recognizing patients at increased risk pre-operatively and using preventive measures where indicated is likely to be key to minimizing the incidence of this complication.

Entities:  

Mesh:

Year:  2005        PMID: 16015088     DOI: 10.1097/01.ico.0000154380.13237.ea

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  9 in total

Review 1.  Development of hydrogel-based keratoprostheses: a materials perspective.

Authors:  David Myung; Pierre-Emile Duhamel; Jennifer R Cochran; Jaan Noolandi; Christopher N Ta; Curtis W Frank
Journal:  Biotechnol Prog       Date:  2008-04-19

2.  Risk factors for the development of retroprosthetic membranes with Boston keratoprosthesis type 1: multicenter study results.

Authors:  Christopher J Rudnisky; Michael W Belin; Amit Todani; Khalid Al-Arfaj; Jared D Ament; Brian J Zerbe; Joseph B Ciolino
Journal:  Ophthalmology       Date:  2012-02-22       Impact factor: 12.079

Review 3.  AlphaCor artificial cornea: clinical outcome.

Authors:  N Jirásková; P Rozsival; M Burova; M Kalfertova
Journal:  Eye (Lond)       Date:  2011-06-17       Impact factor: 3.775

4.  Microkeratome assisted deep lamellar keratoprosthesis.

Authors:  S Shimmura; H Miyashita; Y Uchino; T Taguchi; H Kobayashi; J Shimazaki; J Tanaka; K Tsubota
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

5.  Fyodorov-Zuev keratoprosthesis implantation: long-term results in patients with multiple failed corneal grafts.

Authors:  Alireza Ghaffariyeh; Nazafarin Honarpisheh; Akbar Karkhaneh; Reza Abudi; Zinaida Ivanovna Moroz; Alireza Peyman; Abolhasan Faramarzi; Fuad Abasov
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-27       Impact factor: 3.117

6.  Biocompatibility of poly(ethylene glycol) and poly(acrylic acid) interpenetrating network hydrogel by intrastromal implantation in rabbit cornea.

Authors:  Luo Luo Zheng; Vijay Vanchinathan; Roopa Dalal; Jaan Noolandi; Dale J Waters; Laura Hartmann; Jennifer R Cochran; Curtis W Frank; Charles Q Yu; Christopher N Ta
Journal:  J Biomed Mater Res A       Date:  2015-03-27       Impact factor: 4.396

7.  AlphaCor keratoprosthesis: postoperative development of six patients.

Authors:  S A Holak; H M Holak; H Bleckmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-22       Impact factor: 3.117

8.  Outcomes of the Boston keratoprosthesis in jordan.

Authors:  Wisam A Shihadeh; Hasan M Mohidat
Journal:  Middle East Afr J Ophthalmol       Date:  2012-01

Review 9.  Keratoconus: tissue engineering and biomaterials.

Authors:  Dimitrios Karamichos; Jesper Hjortdal
Journal:  J Funct Biomater       Date:  2014-09-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.